NCM · Biotechnology

NVCT (NVCT) Stock

$19.63 +0.45% NCM: NVCT Healthcare

Valuation

MetricValue
Price$19.63
Market Cap$520.87M
P/E Ratio-7.82
P/B Ratio12.57
P/S Ratio0.00
EPS (TTM)$-1.32
52-Week High$28.53
52-Week Low$5.55
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-144.44%
ROA-81.25%
ROCE-147.37%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio2.46

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-13.0M$-19.0M$-23.0M$-20.0M$-28.0M
Net Profit$-13.0M$-19.0M$-22.0M$-19.0M$-26.0M
EPS$-1.09$-1.51$-1.43$-1.11$-1.32
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$7.0M$20.0M$19.0M$19.0M$32.0M
Total Liabilities$18.0M$6.0M$7.0M$9.0M$13.0M
Cash$6.0M$20.0M$19.0M$19.0M$32.0M
Borrowings$0$0$0$0$0

Latest News

StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data TMX Newsfile · Jul 14, 2026 Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High? Zacks · Jul 8, 2026 Nuvectis Pharma Insider Bought Shares Worth $916,000, According to a Recent SEC Filing MT Newswires · Jul 1, 2026 What Makes Nuvectis Pharma, Inc. (NVCT) a Strong Momentum Stock: Buy Now? Zacks · Jul 1, 2026 Nuvectis Pharma shares slide after pricing $100 million discounted stock offering (NVCT) InvestorsHub · Jun 30, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-10.0M$-14.0M$-16.0M$-12.0M$-16.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$-4.0M$10.0M$0$0
Net Cash Flow$6.0M$14.0M$-1.0M$-1.0M$13.0M
Free Cash Flow$-10.0M$-14.0M$-16.0M$-12.0M$-16.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-6.59%
Quick Ratio2.27
Interest Coverage—
Return 1Y156.36%
Return 3Y38.49%
Return 5Y—

Ownership

Insiders Held35.49%
Institutions Held14.45%
Institutions Float Held22.41%
Institutional HolderSharesReport Date
Blackrock Inc.764,4412026-03-31
Vanguard Capital Management LLC659,8792026-03-31
Iridian Asset Management LLC651,7572026-03-31
Occam Crest Management LP407,1472026-03-31
Geode Capital Management, LLC384,1052026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARMPArmata Pharmaceuticals, Inc. $4.64 -0.43% -0.60 $170.34M 0.00%
CGEN $2.27 -4.83% 7.21 $214.16M 0.00%
CRDF $0.81 -2.98% -2.58 $53.22M 0.00%
CYBNCybin Inc. $8.28 +1.22% -1.67 $413.02M 0.00%
IPHAInnate Pharma S.A. $1.79 +0.14% -2.89 $168.32M 0.00%

About NVCT

NVCT is led by CEO Ron Bentsur, employs 13 people, headquartered in US, publicly traded since 2022.

NVCT stock trades at $19.63 with a market capitalization of $520.87M. The stock is valued at a price-to-earnings (P/E) ratio of -7.82, price-to-book of 12.57, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $5.55 and $28.53, and currently trades 31.2% below its 52-week high.

On profitability, NVCT generates a return on equity (ROE) of -144.44%, return on capital employed of -147.37%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides